Swedish Orphan Biovitrum: Hemophilia A trials

The registry lists 16 Hemophilia A studies with Swedish Orphan Biovitrum as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 1Phase 3 2Phase 4 4No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 4Results posted
• Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI TherapiesCompletedNCT03103542Phase 4Results posted
• Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingNCT06940830Phase 4
• A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisActive, not recruitingNCT06752850Phase 4
• Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingNCT06716814Phase 3
• Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedNCT06579144Phase 1
• A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedNCT05817812Phase 3
• Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)CompletedNCT04731701
• A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint HealthCompletedNCT04293523
• Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint ExaminationCompletedNCT04133883Not applicable
• rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia ACompletedNCT03951103
• A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceCompletedNCT03655340
• Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and BCompletedNCT03276130
• A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or BCompletedNCT03055611
• Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsCompletedNCT02976753
• A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia CareCompletedNCT02049099